What pharmacologic options are recommended for quitting vaping?

Pharmacologic Options for Quitting Vaping

Varenicline 1 mg twice daily for 12 weeks, combined with behavioral counseling, is the most effective first-line medication for stopping nicotine vaping, achieving the highest cessation rates among available pharmacotherapies. 1, 2

First-Line Pharmacotherapy: Varenicline

Varenicline is the preferred initial treatment based on the strongest recent evidence from a 2025 randomized trial showing 51% continuous abstinence during weeks 9-12 versus 14% with placebo (adjusted OR 6.5,95% CI 3.0-14.1), and 28% versus 7% abstinence through 24 weeks (adjusted OR 6.0,95% CI 2.1-16.9). 2 This represents a doubling of quit rates compared to placebo. 3

Dosing Protocol

• Start 0.5 mg once daily for 3 days, then 0.5 mg twice daily for 4 days, followed by the target dose of 1 mg twice daily for at least 12 weeks. 4, 1, 2
• Initiate dosing 1-2 weeks prior to the target quit date to allow therapeutic levels to build. 4
• Schedule follow-up within 2 weeks after starting to assess adherence and manage side effects, particularly nausea. 4, 1

Safety Profile

• Nausea is the most common side effect (occurring in 24-31% of patients), but can be managed with dose adjustments or anti-emetics. 4
• Monitor for neuropsychiatric symptoms including depression, agitation, or suicidal ideation, though these are uncommon—discontinue if they occur. 4, 1
• Varenicline was well tolerated in the 2025 youth vaping trial, with only 2% discontinuing due to adverse events and no drug-related serious adverse events. 2
• Contraindicated in patients with brain metastases due to seizure risk. 4

Alternative First-Line Option: Combination Nicotine Replacement Therapy

Combination NRT (21 mg patch + short-acting form) achieves 36.5% abstinence at 6 months versus 23.4% for patch alone (RR 1.25,95% CI 1.15-1.36), making it a viable alternative when varenicline is not preferred or tolerated. 5, 1

Dosing Protocol

• Apply a 21 mg/24-hour nicotine patch daily to clean, dry, hairless skin on the upper body or outer arm, rotating sites daily. 5, 1
• Add short-acting NRT for breakthrough cravings: use 4 mg nicotine gum for highly dependent vapers (first vape within 30 minutes of waking) or 2 mg gum for less dependent users, with 8-12 pieces per day as needed. 5, 1
• Alternative short-acting options include nicotine lozenge, nasal spray, or inhaler—all have similar efficacy. 4, 1
• Continue for a minimum of 12 weeks, with the option to extend to 6-12 months to prevent relapse. 4, 5, 1

Safety Considerations

• Combination NRT is completely safe—blood nicotine levels remain significantly lower than from vaping, making toxicity rare even when used concurrently with vaping. 5, 1
• Safe even in patients with cardiovascular disease, with no increased cardiac risk. 4, 5, 1

Emerging Evidence: Cytisinicline

Cytisinicline (3 mg three times daily for 12 weeks) showed promise in a 2024 trial, achieving 31.8% continuous abstinence at end of treatment versus 15.1% with placebo (OR 2.64,95% CI 1.06-7.10), though the effect did not reach statistical significance at 16-week follow-up. 6 This represents an emerging option requiring confirmation in larger trials. 6

Essential Behavioral Support Component

Pharmacotherapy must be combined with behavioral counseling—this combination achieves 15.2% quit rates versus 8.6% with brief advice alone. 1

Counseling Framework

• Provide a minimum of 4 sessions of individual or group therapy over 12 weeks, with sessions lasting 10-30+ minutes. 4, 1
• Include skills training, social support, motivational interviewing, and strategies for addressing triggers and developing coping mechanisms. 4, 1
• Text message-based interventions are particularly effective in youth and young adults (ages 13-25), increasing cessation rates by 32% (RR 1.32,95% CI 1.19-1.47). 1, 3
• Telephone counseling is effective when providing at least 3 calls. 4

Treatment Algorithm for Initial Failures

When first-line treatment fails, follow this escalation strategy:

1. Switch to the alternative first-line medication not previously used (varenicline ↔ combination NRT). 1
2. Extend treatment duration to 6-12 months rather than the standard 12 weeks. 4, 1
3. Intensify behavioral therapy progressively, with referral to specialty care (psychiatrist, psychologist) as indicated. 4
4. If reduction efforts stall or total abstinence seems unlikely, consider switching pharmacotherapy rather than persisting with an ineffective regimen. 4

Special Population Considerations

• Youth and young adults (ages 16-25): Varenicline demonstrated efficacy and safety in this population, with 51% abstinence at end of treatment. 2
• Former smokers who vape: The same pharmacotherapy protocols apply—varenicline and combination NRT are both effective regardless of smoking history. 2, 6
• Dual users (vaping + smoking): Address both nicotine sources; preliminary evidence suggests mono-vapers may respond better to NRT than dual users. 7

Critical Clinical Pearls

• Nicotine withdrawal symptoms peak within 1-2 weeks then subside—encourage continued therapy through brief lapses rather than abandoning treatment. 4, 1
• Do not discontinue treatment prematurely even if the patient has a brief slip; patients who do not quit immediately may quit later after withdrawal symptoms subside. 4
• Indefinite NRT may be necessary in some patients to prevent relapse, which is preferable to returning to vaping. 1
• Track smoking status at every follow-up to ensure dual users are not relapsing to combustible tobacco. 1

Common Pitfalls to Avoid

• Using monotherapy when combination therapy is indicated: Single-form NRT is substantially less effective than combination NRT. 5
• Inadequate treatment duration: Stopping at 8 weeks instead of the recommended minimum 12 weeks reduces success rates. 4, 1
• Providing pharmacotherapy without behavioral support: This reduces effectiveness by approximately 3 percentage points. 4
• Failing to follow up within 2 weeks: Early assessment is critical for managing side effects and reinforcing adherence. 4, 1